Regeneron Pharmaceuticals, Inc. (REGN)
Automate Your Wheel Strategy on REGN
With Tiblio's Option Bot, you can configure your own wheel strategy including REGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol REGN
- Rev/Share 132.0122
- Book/Share 275.4227
- PB 1.9804
- Debt/Equity 0.092
- CurrentRatio 4.9267
- ROIC 0.1024
- MktCap 57899488080.0
- FreeCF/Share 28.3046
- PFCF 19.1714
- PE 12.9355
- Debt/Assets 0.072
- DivYield 0.0032
- ROE 0.1477
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | REGN | Argus | Buy | Hold | -- | -- | June 30, 2025 |
| Downgrade | REGN | Wells Fargo | Overweight | Equal Weight | -- | $580 | May 30, 2025 |
| Downgrade | REGN | RBC Capital Mkts | Outperform | Sector Perform | -- | $662 | May 30, 2025 |
| Upgrade | REGN | Citigroup | Neutral | Buy | -- | $700 | May 14, 2025 |
| Resumed | REGN | Cantor Fitzgerald | -- | Overweight | -- | $695 | April 22, 2025 |
| Upgrade | REGN | Leerink Partners | Market Perform | Outperform | $762 | $834 | Feb. 5, 2025 |
| Downgrade | REGN | UBS | Buy | Neutral | $1130 | $738 | Jan. 16, 2025 |
| Resumed | REGN | BofA Securities | -- | Underperform | -- | $565 | Dec. 10, 2024 |
| Downgrade | REGN | Leerink Partners | Outperform | Market Perform | $1175 | $1077 | Sept. 24, 2024 |
News
Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132493&wire=1 or contact Joseph E. Levi, Esq.
Read More
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).
Read More
Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132477&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy.
Read More
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period").
Read More
Shareholders that lost money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132279&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit – REGN
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132235&wire=1 or contact Joseph E. Levi, Esq.
Read More
Investors who lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132232&wire=1 or contact Joseph E. Levi, Esq.
Read More
REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period"), have until Monday, March 10, 2025 to seek appointment as lead plaintiff of the Regeneron class action lawsuit. Captioned Radtke v.
Read More
Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132198&wire=1 or contact Joseph E. Levi, Esq.
Read More
REGN Deadline: REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period"), of the important March 10, 2025 lead plaintiff deadline. So what: If you purchased Regeneron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132148&wire=1 or contact Joseph E. Levi, Esq.
Read More
REGN DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 25, 2025 / WHY: New York, N.Y., February 25, 2025.
Read More
Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132134&wire=1 or contact Joseph E. Levi, Esq.
Read More
REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132064&wire=1 or contact Joseph E. Levi, Esq.
Read More
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 25, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period").
Read More
Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024.
Read More
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period"), of the important March 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Regeneron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=131882&wire=1 or contact Joseph E. Levi, Esq.
Read More
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts– Hagens Berman
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
REGN Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline REGN Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline
Read More
Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearing Speech and development progress followed dramatic improvements in hearing in first child treated in the trial TARRYTOWN, N.Y., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have profound genetic hearing loss due to variants of the otoferlin (OTOF) gene.
Read More
Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=131820&wire=1 or contact Joseph E. Levi, Esq.
Read More
The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 2, 2023 and October 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 10, 2025.
Read More
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period").
Read More
Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact The Gross Law Firm about pending Class Action - REGN
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
Published: February 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=131637&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
Published: February 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”), of the important March 10, 2025 lead plaintiff deadline.
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=131428&wire=1 or contact Joseph E. Levi, Esq.
Read More
About Regeneron Pharmaceuticals, Inc. (REGN)
- IPO Date 1991-04-02
- Website https://www.regeneron.com
- Industry Biotechnology
- CEO Leonard S. Schleifer
- Employees 15158